By Ji Lee and accompanying this NY Times opinion piece.
Masthead
Editors in Chief
Austin Frakt
Aaron Carroll
Managing Editor
Adrianna McIntyre
Contributors
Kevin Outterson
Bill Gardner
Nicholas Bagley
Other ContributorsRecent posts
- A Variety of Vaccines: A History of Vaccine Development, Part II
- Variolation, Innoculation, and Vaccination: A History, Part I
- What can we expect from re-opening HealthCare.gov? Hope.
- The Rising Crisis of Underinsurance: How the Biden Administration May Shape Inequities in Patient Affordability
- How Genomics Improve Cancer Survival and Patient Quality of Life: The Healthcare Triage Podcast
- The End of Surprise Billing for Medical Care?
- Drug Prices by Committee: One Way Biden Could Lower Costs
- Recent publications from Boston University’s Department of Health Law, Policy and Management: February 2021 Edition
- Out-of-network payments in Medicare Advantage
- Cancer Journal: What is health?
Archives
For speaking inquiries
Interested in having Aaron or Austin speak to your group?
For information on Aaron speaking, click here.
For information on Austin speaking, contact the Leigh Bureau.
Aaron’s stuff
Selected appearances:
The Colbert Report
Good Morning America
Sound Medicine (most recent)
The Ed ShowAustin’s stuff
Click here for links to Austin’s peer-reviewed publications and/or related posts.
Health care maze
12/08/2012
Austin Frakt
item.php
Follow the blog
TIE Books
Amazon.com
Barnes & Noble
Indiebound
iBooks
Google
Kobo
Amazon.com
Barnes & Noble
Books-A-Million
iBooks
IndieBound
Powells
Buy at Amazon.com
Summary
Excerpt: Economic profit
Excerpt: Diminishing marginal utility
Excerpt: Four factors of production
Excerpt: Monopoly marginal revenue
Excerpt: Consumer/producer surplus
Amazon.com
Barnes & Noble
Books-A-Million
Borders
IndieBound
Powells
Borders
Barnes & Noble
IndieBound
Amazon.com
Books-A-Million
Powells
Austin and Aaron are participants in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to amazon.com.Tag cloud
ACA AcademyHealth access accountable care organizations Affordable Care Act announcement blogging cancer comic competitive bidding costs cost shifting COVID-19 employer-sponsored health insurance health care costs Healthcare Triage health insurance health insurance mandates health reform hospital readmissions hospitals individual mandate insurance exchange market power Massachusetts Medicaid Medicare Medicare Advantage mortality nutrition obesity On The Record physicians politics PPACA premiums prescription drugs quality reading list reflex RWJF spending uninsured Upshot vaccines
by Weiwen on December 9th, 2012 at 07:35
The picture is funny, bit it and the article really demonstrate how complicated our healthcare system can be.
I mean, the guy in the article had no idea how much his treatment would cost, and nobody could give him any idea. Now, I am changing insurance plans, and I get monthly allergy shots, and I’m not sure how much more or less I’ll be paying out of pocket. But this is not a huge deal, since I am paying $18 per shot now. This guy is potentially paying tens of thousands of dollars out of pocket.
This is why Medicare needs an explicit out of pocket limit imo.
by BenefitJack on December 10th, 2012 at 08:06
Why didn’t he just read the PPACA mandated Summary of Benefits and Coverage. Like all other mandated disclosures, I am sure the SBC would have provided a clear answer to all of his questions.
Someone should tell Time Warner and the participant about ERISA claims procedures.
by SAO on December 10th, 2012 at 09:00
@ Benefits Jack,
If you read the article, the question was, what would be the out-of-pocket cost for a specific expensive drug. For the most promising policy, the answer depended on the price that the CVS had contracted with the insurer to
Part of the question was what was the price CVS charged members of the health plan which had contracted with CVS to provide some degree of drug coverage. And even CVS had trouble answering the question.
I doubt the mandated summary of benefits covers individual drug prices.
by Benefit jack on December 12th, 2012 at 17:42
@sao.
Sorry. Just trying to sarcastically note:
Companies spending billions on dislosures no one wants or asked for, and no one uses, or reads with a “near death” financial penalty for non compliance, and
A participant and company should know how to use claims/appeals process to get accurate answers.
Just ask dol/IRS/HHS and they’ll tell you how the tens of billions spent on ppaca compliance is solving participant problems,meeting needs.
by Marc Brown on December 10th, 2012 at 09:32
Here in England Revlimid is free to the over 60s. The cost to the NHS has been negotiated at about $57,000 a year for the first two years and those still taking the drug after that have the entire cost paid by the manufacturer. Surely it’s an abdication of responsibility for the US government not to negotiate similar deals for Medicare.